Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Roche Holding Ltd. : Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/23/2011 | 07:22am CET

Basel, 23 December, 2011

Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer

Avastin represents first major treatment advance for women with ovarian cancer in 15 years

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer.

Ovarian cancer is the most deadly of the gynaecological cancers, with approximately 220,000 women diagnosed and 140,000 women dying from the disease each year globally.  The approval of Avastin marks a major advance in the treatment of women with ovarian cancer for whom treatment has been limited to surgery and chemotherapy.

"Today's approval of Avastin marks the first major treatment advance in newly diagnosed ovarian cancer in 15 years," said Hal Barron M.D., Chief Medical Officer and Head, Global Product Development. "This is the fifth tumor type for which Avastin has been approved in Europe, making it one of few biologic drugs indicated for multiple cancers."

Avastin has demonstrated in two phase III studies (GOG0218 and ICON7) that women with newly diagnosed advanced ovarian cancer who received Avastin plus chemotherapy and then continued on Avastin alone lived significantly longer without their disease getting worse (progression-free survival) compared to those who received chemotherapy only.

Ovarian cancer is associated with high concentrations of vascular endothelial growth factor (VEGF), a protein associated with tumour growth and spread. Avastin precisely inhibits VEGF, high levels of which are associated with ascites development (excess fluid in the body cavity), disease worsening, and a poorer prognosis in ovarian cancer patients.

About Ovarian Cancer

Ovarian cancer is the eighth most commonly diagnosed cancer in women and the seventh leading cause of cancer death among women worldwide. Annually, over 220,000 women will be diagnosed with ovarian cancer around the world and approximately 140,000 will die from the disease.1

Surgery to remove as much of the tumor as possible, followed by chemotherapy, is a mainstay of treatment but unfortunately, the majority of patients are diagnosed with late stage disease (when the cancer has grown or spread) and they require further treatment.

Avastin in Ovarian Cancer: Research Programme

Roche has an extensive research and clinical trial programme investigating Avastin in patients with ovarian cancer in both the front-line and recurrent setting (when the cancer has returned after initial therapy), in order to help improve treatment outcomes for women with ovarian cancer.

Avastin has so far demonstrated a significant improvement in the time women with ovarian cancer live without the disease getting worse (progression free survival; PFS) in three large phase III studies (GOG 0218 and ICON7 in the front-line setting and OCEANS in the recurrent, platinum-sensitive setting).

This approval will enable the use of Avastin in combination with carboplatin and paclitaxel for the front-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, primary peritoneal or fallopian tube cancer for women in Europe. Avastin is administered in addition to chemotherapy for up to 6 cycles of treatment followed by continued use of Avastin as single agent until disease progression or for a maximum of 15 months or until unacceptable toxicity, whichever occurs earlier. The recommended dose of Avastin is 15mg/kg of bodyweight given once every 3 weeks as an intravenous infusion.

Roche is committed to establishing the full potential of Avastin in ovarian cancer through continued research with other agents and in other settings.

About Avastin: Over 5 Years of Transforming Cancer Care

With the initial approval in the USA for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced cancer.

Today, Avastin is continuing to transform cancer care through its proven survival benefit (overall survival and/or progression free survival) across several types of cancer. Avastin is approved in Europe for the treatment of advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer and kidney cancer, and is also available in the US for the treatment of colorectal cancer, non-small cell lung cancer and kidney cancer. In addition, Avastin is approved in the US and over 30 other countries for the treatment of patients with glioblastoma (a type of brain cancer). Avastin is also approved in Japan for the treatment of inoperable or recurrent breast cancer. Avastin is the only anti-angiogenic therapy available for the treatment of these numerous advanced cancer types, which collectively cause over 2.5 million deaths each year.

Avastin has made anti-angiogenic therapy a fundamental pillar of cancer treatment today - over one million patients have been treated with Avastin so far. A comprehensive clinical programme with more than 500 ongoing clinical trials is investigating the use of Avastin in over 50 tumor types (including colorectal, breast, non-small cell lung, brain, gastric, ovarian and others) and different settings (advanced or early stage disease).

About Avastin: Mode of Action

Avastin is an antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumor angiogenesis - a fundamental process required for a tumor to grow and to spread (metastasise) to other parts of the body. Avastin's precise mode of action allows it to be combined effectively with a broad range of chemotherapies and other anti-cancer treatments. Avastin helps to control tumor growth and extend survival with only a limited impact on the side effects of chemotherapy.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
12/08 CHUGAI PHARMACEUTICAL : Findings from Chugai Pharmaceutical Yields New Data on H..
12/08 FOUNDATION MEDICINE : Researchers at Foundation Medicine Inc. Report New Data on..
12/08 ROCHE : University of Southampton - New cancer drug shows promise in helping pat..
12/08 ROCHE : Avastin (bevacizumab) plus chemotherapy receives FDA approval for platin..
12/08 Sanofi mulls counterbid for Actelion amid J&J talks
12/08 ROCHE : announces European approval of Venclyxto for people with hard-to-treat c..
12/08 ROCHE : Morgan Freeman Joins Stand Up to Cancer, Genentech in New PSA
12/07 ROCHE : FDA Approves Genentech's Avastin (Bevacizumab) Plus Chemotherapy for a S..
12/07 ROCHE : New cancer drug shows promise in helping patients with blood cancer
12/07 FOUNDATION MEDICINE INC. : Receives Average Recommendation of Hold from Analysts
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/09 CANCER IMMUNOTHERAPY MARKET : 2016 Takeaways And What To Expect In 2017
12/08 Companies Look To Fill Brain Metastasis Niche
12/08 Roche's Venclyxto conditionally approved in Europe
12/06 FDA OKs new use of Roche's Avastin in specific type of advanced ovarian cance..
12/06 Early Data For Next Generation Of Imbruvica's Challengers
Advertisement
Financials ( CHF)
Sales 2016 51 112 M
EBIT 2016 17 690 M
Net income 2016 11 162 M
Debt 2016 11 052 M
Yield 2016 3,75%
P/E ratio 2016 17,62
P/E ratio 2017 15,82
EV / Sales 2016 4,08x
EV / Sales 2017 3,79x
Capitalization 197 256 M
More Financials
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 284  CHF
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-17.58%193 824
JOHNSON & JOHNSON9.29%305 407
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
MERCK & CO., INC.15.92%168 820
SANOFI-2.89%104 027
More Results